A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT00900731. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
Study identification
- NCT ID
- NCT00900731
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,598 participants
Conditions and interventions
Conditions
Interventions
- Indacaterol 150 μg Drug
- Tiotropium 18 μg Drug
- Placebo to indacaterol Drug
- Placebo to tiotropium Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Feb 28, 2010
- Completion
- Feb 28, 2010
- Last update posted
- Aug 18, 2011
2009 – 2010
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35209 | — |
| Novartis Investigator Site | Jasper | Alabama | 35501 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85050 | — |
| Novartis Investigative Site | Tucson | Arizona | 85723 | — |
| Novartis Investigator Site | Anaheim | California | 92801 | — |
| Novartis Investigator Site | Stockton | California | 95207 | — |
| Novartis Investigator Site | Walnut Creek | California | 94598 | — |
| Novartis Investigator Site | Fort Collins | Colorado | 80528 | — |
| Novartis Investigator Site | Wheat Ridge | Colorado | 80033 | — |
| Novartis Investigative Site | South Miami | Florida | 33143 | — |
| Novartis Investigator Site | Normal | Illinois | 61761 | — |
| Novartis Investigative Site | Evansville | Indiana | 47710 | — |
| Novartis Investigative Site | Topeka | Kansas | 66606 | — |
| Novartis Investigative Site | Lafayette | Louisiana | 70503 | — |
| Novartis Investigative Center | Saint Charles | Missouri | 63301 | — |
| Novartis Investigative Site | St Louis | Missouri | 63141 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68510 | — |
| Novartis Investigative Site | Henderson | Nevada | 89014 | — |
| Novartis Investigative Site | Albany | New York | 12205 | — |
| Novartis Investigative Site | Larchmont | New York | 10538 | — |
| Novartis Investigative Site | New York | New York | 10016 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28207 | — |
| Novartis Investigative Site | Columbus | Ohio | 43214 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Richmond | Virginia | 23229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 187 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00900731, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2011 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00900731 live on ClinicalTrials.gov.